Clinical trial · Observational
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
Minimal Residual Disease (MRD) Guided Prognosis Prediction and Adjuvant Treatment Based on Expression and Mutational Signatures of Circulating Tumor Cell (CTC) and Circulating Tumor DNA (ctDNA) in Non-small Cell Lung Cancer
NCT06198868CI-TRIAL-00072949recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Operable | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Operable group
- description
- Early-stage patients with radical surgery or operable patients with neoadjuvant treatment
- interventionNames
- Procedure: Operable
- label
- Inoperable group
- description
- Advanced-stage patients receive non-surgery therapies.
Primary outcomes (1)
- measure
- To evaluate the Progression-free Survival (PFS)
- timeFrame
- From the first study dose date to the date of first documentation of disease progression or death (whichever occurred first), up to approximately 3 years
- description
- Progression-free survival (PFS) is defined as the time from the start of treatment to the occurrence of tumor progression or death due to any cause based on RECIST 1.1 assessed by investigator review.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent must be signed before implementing any enrollment-related procedures; 2. Age ≥18 years old; 3. Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)； 4. There is no special restriction on the source of genetic test report. 5. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion. 6. Have not received any previous systemic antitumor therapy for advanced diseases. 7. No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system. 8. ECOG score: 0-1; 9. Expected survival time \> 3 months. Exclusion Criteria: 1. Received surgical treatment for lung tumors. 2. Received neoadjuvant chemotherapy or radiotherapy. 3. Received cellular therapy within the last 1 year. 4. Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases. 5. Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.
References
Publications (0)
Data not yet available
No reference posted for this study.